Kurs
-0,02%
Likviditet
8 962 MSEK
Kalender
| Est. tid* | ||
| 2025-04-29 | 08:00 | Kvartalsrapport 2025-Q1 |
| 2025-04-11 | N/A | Årsstämma |
| 2025-02-21 | - | X-dag halvårsutdelning AZN 1.05 |
| 2025-02-20 | - | X-dag halvårsutdelning AZN 22.96 |
| 2025-02-06 | - | Bokslutskommuniké 2024 |
| 2024-11-12 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-08 | - | X-dag halvårsutdelning AZN 77.600002 |
| 2024-07-25 | - | Kvartalsrapport 2024-Q2 |
| 2024-04-25 | - | Kvartalsrapport 2024-Q1 |
| 2024-04-11 | - | Årsstämma |
| 2024-02-22 | - | X-dag halvårsutdelning AZN 20.65 |
| 2024-02-08 | - | Bokslutskommuniké 2023 |
| 2023-11-09 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-10 | - | X-dag halvårsutdelning AZN 9.64 |
| 2023-07-28 | - | Kvartalsrapport 2023-Q2 |
| 2023-04-27 | - | Årsstämma |
| 2023-04-27 | - | Kvartalsrapport 2023-Q1 |
| 2023-02-23 | - | X-dag halvårsutdelning AZN 20.69 |
| 2023-02-09 | - | Bokslutskommuniké 2022 |
| 2022-11-10 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-11 | - | X-dag halvårsutdelning AZN 9.49 |
| 2022-07-29 | - | Kvartalsrapport 2022-Q2 |
| 2022-04-29 | - | Årsstämma |
| 2022-04-29 | - | Kvartalsrapport 2022-Q1 |
| 2022-02-24 | - | X-dag halvårsutdelning AZN 1.97 |
| 2022-02-10 | - | Bokslutskommuniké 2021 |
| 2021-11-12 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-12 | - | X-dag halvårsutdelning AZN 7.72 |
| 2021-07-29 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-11 | - | Årsstämma |
| 2021-04-30 | - | Kvartalsrapport 2021-Q1 |
| 2021-02-25 | - | X-dag halvårsutdelning AZN 15.76 |
| 2021-02-11 | - | Bokslutskommuniké 2020 |
| 2020-11-05 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-13 | - | X-dag halvårsutdelning AZN 7.87 |
| 2020-07-30 | - | Kvartalsrapport 2020-Q2 |
| 2020-04-29 | - | Årsstämma |
| 2020-04-29 | - | Kvartalsrapport 2020-Q1 |
| 2020-02-27 | - | X-dag halvårsutdelning AZN 18.32 |
| 2020-02-14 | - | Bokslutskommuniké 2019 |
| 2019-10-24 | - | Kvartalsrapport 2019-Q3 |
| 2019-08-08 | - | X-dag halvårsutdelning AZN 8.49 |
| 2019-07-25 | - | Kvartalsrapport 2019-Q2 |
| 2019-04-26 | - | Årsstämma |
| 2019-04-26 | - | Kvartalsrapport 2019-Q1 |
| 2019-02-28 | - | X-dag halvårsutdelning AZN 17.46 |
| 2019-02-14 | - | Bokslutskommuniké 2018 |
| 2018-11-08 | - | Kvartalsrapport 2018-Q3 |
| 2018-08-09 | - | X-dag halvårsutdelning AZN 7.92 |
| 2018-07-26 | - | Kvartalsrapport 2018-Q2 |
| 2018-05-18 | - | Årsstämma |
| 2018-05-18 | - | Kvartalsrapport 2018-Q1 |
| 2018-02-15 | - | X-dag halvårsutdelning AZN 14.97 |
| 2018-02-02 | - | Bokslutskommuniké 2017 |
| 2017-11-09 | - | Kvartalsrapport 2017-Q3 |
| 2017-08-10 | - | X-dag halvårsutdelning AZN 7.4 |
| 2017-07-27 | - | Kvartalsrapport 2017-Q2 |
| 2017-04-27 | - | Årsstämma |
| 2017-04-27 | - | Kvartalsrapport 2017-Q1 |
| 2017-02-16 | - | X-dag halvårsutdelning AZN 16.57 |
| 2017-02-02 | - | Bokslutskommuniké 2016 |
| 2016-11-10 | - | Kvartalsrapport 2016-Q3 |
| 2016-08-11 | - | X-dag halvårsutdelning AZN 7.81 |
| 2016-07-28 | - | Kvartalsrapport 2016-Q2 |
| 2016-04-29 | - | Årsstämma |
| 2016-04-29 | - | Kvartalsrapport 2016-Q1 |
| 2016-02-18 | - | X-dag halvårsutdelning AZN 16.26 |
| 2016-02-04 | - | Bokslutskommuniké 2015 |
| 2015-11-05 | - | Kvartalsrapport 2015-Q3 |
| 2015-08-13 | - | X-dag halvårsutdelning AZN 7.71 |
| 2015-07-30 | - | Kvartalsrapport 2015-Q2 |
| 2015-04-24 | - | Årsstämma |
| 2015-04-24 | - | Kvartalsrapport 2015-Q1 |
| 2015-02-19 | - | X-dag halvårsutdelning AZN 15.62 |
| 2015-02-05 | - | Bokslutskommuniké 2014 |
| 2014-11-06 | - | Kvartalsrapport 2014-Q3 |
| 2014-08-13 | - | X-dag halvårsutdelning AZN 6.2 |
| 2014-07-31 | - | Kvartalsrapport 2014-Q2 |
| 2014-04-24 | - | Årsstämma |
| 2014-04-24 | - | Kvartalsrapport 2014-Q1 |
| 2014-02-19 | - | X-dag halvårsutdelning AZN 129.777777 |
| 2014-02-06 | - | Bokslutskommuniké 2013 |
| 2013-10-31 | - | Kvartalsrapport 2013-Q3 |
| 2013-08-14 | - | X-dag halvårsutdelning AZN 65.777779 |
| 2013-08-01 | - | Analytiker möte 2013 |
| 2013-08-01 | - | Kvartalsrapport 2013-Q2 |
| 2013-04-25 | - | Årsstämma |
| 2013-04-25 | - | Kvartalsrapport 2013-Q1 |
| 2013-02-13 | - | X-dag halvårsutdelning AZN 133.888888 |
| 2013-01-31 | - | Bokslutskommuniké 2012 |
| 2012-10-25 | - | Analytiker möte 2012 |
| 2012-10-25 | - | Kvartalsrapport 2012-Q3 |
| 2012-08-08 | - | X-dag halvårsutdelning AZN 64.555556 |
| 2012-07-26 | - | Kvartalsrapport 2012-Q2 |
| 2012-04-26 | - | Årsstämma |
| 2012-04-26 | - | Kvartalsrapport 2012-Q1 |
| 2012-02-15 | - | X-dag halvårsutdelning AZN 137.333333 |
| 2012-02-02 | - | Bokslutskommuniké 2011 |
| 2011-10-27 | - | Kvartalsrapport 2011-Q3 |
| 2011-08-03 | - | X-dag halvårsutdelning AZN 57.666665 |
| 2011-07-28 | - | Kvartalsrapport 2011-Q2 |
| 2011-04-28 | - | Årsstämma |
| 2011-04-28 | - | Kvartalsrapport 2011-Q1 |
| 2011-02-02 | - | X-dag halvårsutdelning AZN 129.666662 |
| 2011-01-27 | - | Bokslutskommuniké 2010 |
| 2010-10-28 | - | Kvartalsrapport 2010-Q3 |
| 2010-08-04 | - | X-dag halvårsutdelning AZN 5.12 |
| 2010-07-29 | - | Kvartalsrapport 2010-Q2 |
| 2010-04-29 | - | Kvartalsrapport 2010-Q1 |
| 2010-02-03 | - | X-dag halvårsutdelning AZN 12.43 |
| 2010-01-28 | - | Bokslutskommuniké 2009 |
| 2009-10-29 | - | Kvartalsrapport 2009-Q3 |
| 2009-08-05 | - | X-dag halvårsutdelning AZN 4.41 |
| 2009-07-30 | - | Kvartalsrapport 2009-Q2 |
| 2009-04-30 | - | Årsstämma |
| 2009-04-30 | - | Kvartalsrapport 2009-Q1 |
| 2009-02-04 | - | X-dag halvårsutdelning AZN 12.02 |
| 2008-08-06 | - | X-dag halvårsutdelning AZN 3.34 |
| 2008-02-06 | - | X-dag halvårsutdelning AZN 8.61 |
| 2007-08-08 | - | X-dag halvårsutdelning AZN 3.49 |
| 2007-02-07 | - | X-dag halvårsutdelning AZN 8.6 |
| 2006-08-09 | - | X-dag halvårsutdelning AZN 3.6 |
| 2006-02-08 | - | X-dag halvårsutdelning AZN 7.02 |
| 2005-08-10 | - | X-dag halvårsutdelning AZN 2.99 |
| 2005-02-09 | - | X-dag halvårsutdelning AZN 4.497 |
| 2004-08-11 | - | X-dag halvårsutdelning AZN 2.2 |
| 2004-02-18 | - | X-dag halvårsutdelning AZN 3.91 |
| 2003-08-20 | - | X-dag halvårsutdelning AZN 2.07 |
| 2003-02-19 | - | X-dag halvårsutdelning AZN 3.99 |
| 2002-08-21 | - | X-dag halvårsutdelning AZN 2.21 |
| 2002-02-20 | - | X-dag halvårsutdelning AZN 5.01 |
| 2001-08-22 | - | X-dag halvårsutdelning AZN 2.44 |
| 2001-02-21 | - | X-dag halvårsutdelning AZN 4.49 |
| 2000-09-04 | - | X-dag halvårsutdelning AZN 2.1 |
| 2000-03-08 | - | X-dag halvårsutdelning AZN 4.01 |
| 1999-09-06 | - | X-dag halvårsutdelning AZN 1.89 |
| 1999-04-01 | - | Split AZN 1:0.5045 |
| 1997-05-26 | - | Split AZN 1:2 |
| 1993-06-14 | - | Split AZN 1:5 |
| 1987-06-04 | - | Split AZN 1:2 |
Beskrivning
| Land | Storbritannien |
|---|---|
| Lista | Large Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
5 March 2025
Transactions by Persons Discharging Managerial Responsibilities
AstraZeneca PLC (the Company) announced that, on 4 March 2025, certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) were granted awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) under the terms of the AstraZeneca Deferred Bonus Plan (AZDBP) and the AstraZeneca Performance Share Plan (AZPSP), as detailed in the table below.
| PDMR |
Position |
Ordinary Shares granted under the AZDBP |
Ordinary Shares granted under the AZPSP |
Award price per Ordinary Share |
| Pascal Soriot |
Executive Director and Chief Executive Officer |
14,623 |
109,781 |
£119.63 |
| Aradhana Sarin |
Executive Director and Chief Financial Officer |
6,243 |
45,494 |
£119.63 |
The AZDBP award represents the portion of each PDMR's annual bonus for 2024 that they are required to defer into shares. The Ordinary Shares granted under the AZDBP are subject to a three-year holding period and are due to vest on the third anniversary of grant.
The AZPSP award is subject to a combination of performance measures focused on scientific, commercial, financial and sustainability performance. The performance measures will be assessed over a three-year performance period (1 January 2025 to 31 December 2027). The Ordinary Shares granted under the AZPSP are subject to a two-year holding period following the performance period, and are due to vest on the fifth anniversary of grant.
Details of the performance measures attached to the AZPSP award can be found in the Directors' Remuneration Report within the AstraZeneca Annual Report and Form 20-F Information 2024, which is available on the Company's website at www.astrazeneca.com/annualreport2024 .
Further details are set out in the attached notification, made in accordance with the requirements of the EU Market Abuse Regulation (as it forms part of UK law pursuant to the European Union (Withdrawal) Act 2018).
| 1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
| a) |
Name |
Pascal Soriot |
||||
| 2 |
Reason for the notification |
|||||
| a) |
Position/status |
Chief Executive Officer |
||||
| b) |
Initial notification /Amendment |
Initial notification |
||||
| 3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
| a) |
Name |
AstraZeneca PLC |
||||
| b) |
LEI |
PY6ZZQWO2IZFZC3IOL08 |
||||
| 4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
| a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292 |
||||
| b) |
Nature of the transaction |
Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan |
||||
| c) |
Price(s) and volume(s) |
|
||||
| d) |
Aggregated information - Aggregated volume - Price |
Not applicable - single transaction |
||||
| e) |
Date of the transaction |
4 March 2025 |
||||
| f) |
Place of the transaction |
Outside a trading venue |
||||
| 1 |
Details of the person discharging managerial responsibilities / person closely associated |
|||||
| a) |
Name |
Aradhana Sarin |
||||
| 2 |
Reason for the notification |
|||||
| a) |
Position/status |
Chief Financial Officer |
||||
| b) |
Initial notification/Amendment |
Initial notification |
||||
| 3 |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|||||
| a) |
Name |
AstraZeneca PLC |
||||
| b) |
LEI |
PY6ZZQWO2IZFZC3IOL08 |
||||
| 4 |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|||||
| a) |
Description of the financial instrument, type of instrument Identification code |
Ordinary Shares of US$0.25 each in AstraZeneca PLC GB0009895292 |
||||
| b) |
Nature of the transaction |
Grants of share awards under the AstraZeneca Performance Share Plan and the AstraZeneca Deferred Bonus Plan |
||||
| c) |
Price(s) and volume(s) |
|
||||
| d) |
Aggregated information - Aggregated volume - Price |
Not applicable - single transaction |
||||
| e) |
Date of the transaction |
4 March 2025 |
||||
| f) |
Place of the transaction |
Outside a trading venue |
||||
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialisation of prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals, including Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca's innovative medicines are sold in more than 125 countries and used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on social media @AstraZeneca
Contacts
For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .
Adrian Kemp
Company Secretary
AstraZeneca PLC